An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Clinical trial NCT01187381 · TERMINATED
Trial details
- NCT number
- NCT01187381
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Study type
- OBSERVATIONAL
- Start date
- 2010-04-14
- Primary completion
- 2015-10-15
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.